Smoking Cessation Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Smoking Cessation Overview

Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes,cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.

“Smoking Cessation Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Smoking Cessation Market.

The Smoking Cessation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Smoking Cessation Pipeline Report:

• Companies across the globe are diligently working toward developing novel Smoking Cessation treatment therapies with a considerable amount of success over the years. Smoking Cessation Key players such as – Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics (NFL Biosciences SAS), and others, are developing therapies for the Smoking Cessation treatment 
• Smoking Cessation Emerging therapies such as – AXS-05, Cytisinicline, Nadolol (INV102), NFL-101, and others are expected to have a significant impact on the Smoking Cessation market in the coming years.   

Route of Administration

Smoking Cessation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Smoking Cessation Pipeline Therapeutics Assessment

• Smoking Cessation Assessment by Product Type
• Smoking Cessation By Stage and Product Type
• Smoking Cessation Assessment by Route of Administration
• Smoking Cessation By Stage and Route of Administration
• Smoking Cessation Assessment by Molecule Type
• Smoking Cessation by Stage and Molecule Type

DelveInsight’s Smoking Cessation Report covers around 13+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Smoking Cessation Drugs Under Different Phases of Clinical Development Include:

• AXS-05: Axsome Therapeutics
• Cytisinicline: Achieve Life Sciences
• Nadolol (INV102): Chronic Airway Therapeutics
• NFL-101: Smoke Free Therapeutics (NFL Biosciences SAS)

Get a Free Sample PDF Report to know more about Smoking Cessation Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/smoking-cessation-pipeline-insight

Smoking Cessation Pipeline Analysis:

The Smoking Cessation pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Smoking Cessation with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Smoking Cessation Treatment.
• Smoking Cessation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Smoking Cessation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Smoking Cessation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Smoking Cessation product details are provided in the report. Download the Smoking Cessation pipeline report to learn more about the emerging Smoking Cessation therapies

Smoking Cessation Pipeline Market Drivers

• Research and Development
• Increase in awareness
• Government-mandated warnings on tobacco products

Smoking Cessation Pipeline Market Barriers

• Relapse Cases
• Social Attitudes and Personal Beliefs
• Social Network Barrier
• Patients are not able to use the benefit from Insurers and Health Plans

Scope of Smoking Cessation Pipeline Drug Insight    

• Coverage: Global
• Key Smoking Cessation Companies: Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics (NFL Biosciences SAS), and others
• Key Smoking Cessation Therapies: AXS-05, Cytisinicline, Nadolol (INV102), NFL-101, and others
• Smoking Cessation Therapeutic Assessment: Smoking Cessation current marketed and Smoking Cessation emerging therapies
• Smoking Cessation Market Dynamics: Smoking Cessation market drivers and Smoking Cessation market barriers 

Request for Sample PDF Report for Smoking Cessation Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Smoking Cessation drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com